Severe gastrointestinal reactions warning added to liraglutide labels

Novo Nordisk has updated the prescribing information for both Victoza and Saxenda, its liraglutide-based drugs, to add a new Warnings and Precautions subsection called "Severe Gastrointestinal Adverse Reactions." The change, dated October 2025 on both labels, states that liraglutide use "has been associated with gastrointestinal adverse reactions, sometimes severe," and that the drug "is not recommended in patients with severe gastroparesis" ^[1][2].

Victoza is approved to improve blood sugar control in adults and children age 10 and older with type 2 diabetes, and to lower the risk of major cardiovascular events such as heart attack and stroke in adults with type 2 diabetes and known heart disease ^[2]. Saxenda is approved for chronic weight management in adults and in children age 12 and older with obesity, used alongside a reduced-calorie diet and exercise ^[1]. Both drugs are injectable forms of liraglutide, delivered once daily.

The new gastrointestinal warning appears as section 5.6 in the Victoza label and section 5.7 in the Saxenda label ^[1][2]. It sits alongside other existing warnings already listed for liraglutide products, including risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, and pulmonary aspiration during general anesthesia or deep sedation ^[1][2]. Gastroparesis is a condition in which the stomach empties more slowly than normal; the labels do not define what counts as "severe" gastroparesis or specify how prescribers should assess it before starting treatment.

Both labels already listed nausea, diarrhea, vomiting, constipation, and dyspepsia among the most common adverse reactions seen in clinical trials, each occurring in 5% or more of patients ^[1][2]. The new warning does not change those known common side effect rates. It formalizes, in a distinct labeled section, that GI reactions can be severe and that the drug should not be used in patients with severe gastroparesis — a caution that was not broken out as its own subsection before this update.

Why it matters for patients

For people currently taking Victoza or Saxenda, or considering starting either drug, the labeling change signals that regulators and the manufacturer see gastrointestinal reactions as serious enough to warrant their own dedicated warning, rather than being covered only under general adverse reaction listings. This is a labeling update, not a new restriction on who can be prescribed the drug in general — the language says severe gastroparesis is "not recommended," language distinct from an outright contraindication like the ones already listed for personal or family history of medullary thyroid carcinoma or MEN 2 ^[1][2].

Patients with a history of stomach-emptying problems, or those who develop persistent vomiting, severe abdominal pain, or an inability to keep food or fluids down while on liraglutide, may want to discuss this new warning with their prescriber, since the label change reflects reporting of GI reactions that were sometimes severe ^[1][2]. The sources do not specify the number or details of the adverse event reports that prompted this addition, so the scale of the underlying safety signal is not known from the labels alone.

It is not yet known from these sources whether the FDA required this change, whether it applies to other GLP-1 drugs beyond liraglutide products, or whether similar language will be added to semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) labels, which are chemically different molecules made by different processes despite sharing a drug class.

What happens next

The Victoza label lists a revision date of October 2025, and both labels show the gastrointestinal warning as a "recent major change" effective that month ^[1][2]. The Saxenda label also notes a separate, unrelated change — removal of a suicidal behavior and ideation warning subsection — dated February 2026 ^[1]. No further scheduled label updates specific to this gastrointestinal warning are described in the available sources.